Response to COVID-19 mRNA Vaccination in Patients with Multiple Sclerosis on anti-CD20 Disease Modifying Therapies

被引：0
|
作者：
Wolf, Andrew [1 ]
Pratt, Robert W. [1 ]
Crooks, Kristy [2 ,3 ]
Borko, Tyler [1 ]
Gonzalez, Jose Parra [1 ]
Vollmer, Timothy [1 ]
Frazer-Abel, Ashley [4 ,5 ]
机构：
[1] Univ Colorado, Dept Neurol, Aurora, CO USA
[2] Univ Colorado, Sch Med, Colorado Mol Correlates Lab CMOCO, Aurora, CO USA
[3] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA
[4] Univ Colorado, Sch Med, Exsera BioLabs, Aurora, CO USA
[5] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Aurora, CO USA
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
340
引用
收藏
页码：S179 / S180
页数：2
相关论文
共 50 条
  • [41] Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Petereit, Hela-Felicitas
    Tumani, Hayrettin
    Zettl, Uwe K.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [42] Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Piquet, Amanda L.
    Corboy, John R.
    Vollmer, Timothy L.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [43] A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies
    Stoll, Sharon
    Desai, Shree
    Levit, Elle
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [44] Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
    Montero-Escribano, Paloma
    Matias-Guiu, Jorge
    Gomez-Iglesias, Patricia
    Porta-Etessam, Jesus
    Pytel, Vanesa
    Matias-Guiu, Jordi A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 42
  • [45] Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study
    Moser, Tobias
    O'Sullivan, Ciara
    Otto, Ferdinand
    Hitzl, Wolfgang
    Pilz, Georg
    Schwenker, Kerstin
    Mrazek, Cornelia
    Haschke-Becher, Elisabeth
    Trinka, Eugen
    Wipfler, Peter
    Harrer, Andrea
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
  • [46] Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
    Mazziotti, Valentina
    Crescenzo, Francesco
    Tamanti, Agnese
    Dapor, Caterina
    Ziccardi, Stefano
    Guandalini, Maddalena
    Colombi, Annalisa
    Camera, Valentina
    Peloso, Angela
    Pezzini, Francesco
    Turano, Ermanna
    Marastoni, Damiano
    Calabrese, Massimiliano
    BIOMEDICINES, 2022, 10 (12)
  • [47] Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Magalashvili, David
    Sonis, Polina
    Dolev, Mark
    Menascu, Shay
    Flechter, Shlomo
    Falb, Rina
    Gurevich, Michael
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [48] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Michael Zhong
    Anneke van der Walt
    Maria Pia Campagna
    Jim Stankovich
    Helmut Butzkueven
    Vilija Jokubaitis
    Neurotherapeutics, 2020, 17 : 1768 - 1784
  • [49] EFFECTIVENESS OF COVID-19 VACCINES IN MULTIPLE SCLEROSIS PATIENTS RECEIVING DISEASE-MODIFYING THERAPIES IN ENGLAND
    Garjani, Afagh
    Patel, Sameer
    Law, Graham R.
    Bharkhada, Dhiren
    Rashid, Waqar
    Coles, Alasdair
    Evangelou, Nikos
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [50] Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
    Golshani, Maryam
    Hrdy, Jiri
    VACCINES, 2022, 10 (02)
12345